Kenya BioVax Institute welcomes Dr. Wesley Ronoh as substantive CEO, succeeding Dr. Cecilia Wanjala

KENYA—Dr. Cecilia Wanjala, the Acting CEO of Kenya BioVax Institute Limited, has officially handed over leadership to the new substantive CEO, Dr. Wesley Ronoh.

The handover ceremony took place at the Kenya BioVax headquarters and was presided over by Dr. Charles Githinji, the Chairman of the Board of Directors.

Dr. Ronoh arrives with over 25 years of experience in the pharmaceutical industry, with a strong focus on healthcare development across the African continent.

 Most recently, he served as the Market Shaping Lead for Partnerships for African Vaccine Manufacturing (PAVM) at Africa CDC.

In this role, he guided the Market Design and Demand Intelligence Bold Programme and played a key role in supporting the creation of the African vaccine procurement pooling mechanism.

This initiative aims to streamline vaccine procurement and distribution across Africa.

As a highly skilled pharmacist, Dr. Ronoh holds advanced qualifications, including postgraduate training in Medicinal Chemistry and an MBA.

Throughout his career, he has held senior advisory positions with several major organizations.

These include the Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ GmbH), the European Union, the East African Community, and the Southern African Development Community (SADC Secretariat).

His work with these institutions has involved shaping regional health policies, investment strategies, and improving access to medicines.

Dr. Ronoh’s expertise spans multiple areas critical to the pharmaceutical sector.

These include life science product development, regulatory affairs, intellectual property management, strategic planning, and private sector development.

His comprehensive knowledge and leadership experience make him well-suited to drive Kenya BioVax’s mission forward.

Under Dr. Ronoh’s leadership, Kenya BioVax aims to expand its position as a key player in local vaccine manufacturing.

This move aligns with broader goals to enhance health security in the region by reducing dependence on imported vaccines.

His appointment is expected to bolster the institute’s capacity to innovate and collaborate regionally and internationally.

The transition marks an important step for Kenya BioVax as it continues to strengthen its contributions to Africa’s healthcare landscape.

The Board of Directors expressed confidence in Dr. Ronoh’s ability to lead the organization during this critical period of growth and development.